Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Table of Contents

September 1, 2021; Volume 62,Issue 9

Editor’s Page

  • You have access
    The Annual Journal Impact Factor Saga
    Johannes Czernin
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1177; DOI: https://doi.org/10.2967/jnumed.120.262860

Discussions with Leaders

  • You have access
    Leadership Focus on Advancing Cancer Research and Treatment
    Johannes Czernin, Caius Radu and Antoni Ribas
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1178-1180; DOI: https://doi.org/10.2967/jnumed.121.262937

State of the Art

  • You have access
    Image-Guided High-Intensity Focused Ultrasound, A Novel Application for Interventional Nuclear Medicine?
    Xinrui Zhang, Lisa Landgraf, Nikolaos Bailis, Michael Unger, Thies H. Jochimsen and Andreas Melzer
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1181-1188; DOI: https://doi.org/10.2967/jnumed.120.256230

Hot Topics

  • You have access
    Why Will PET Be the Future of Nuclear Cardiology?
    Marcelo F. Di Carli
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1189-1191; DOI: https://doi.org/10.2967/jnumed.120.254979

Continuing Education

  • You have access
    Systemic Radiopharmaceutical Therapy of Pheochromocytoma and Paraganglioma
    Jorge A. Carrasquillo, Clara C. Chen, Abhishek Jha, Karel Pacak, Daniel A. Pryma and Frank I. Lin
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1192-1199; DOI: https://doi.org/10.2967/jnumed.120.259697

Focus on Molecular Imaging

  • You have access
    Current Landscape in Clinical Pretargeted Radioimmunoimaging and Therapy
    Vilma I.J. Jallinoja and Jacob L. Houghton
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1200-1206; DOI: https://doi.org/10.2967/jnumed.120.260687

Issues and Controversies

  • You have access
    Diversity, Equity, and Inclusion in Academic Nuclear Medicine: National Survey of Nuclear Medicine Residency Program Directors
    Jocelyn L. Cheng, Elizabeth H. Dibble, Grayson L. Baird, Leonie L. Gordon and Hyewon Hyun
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1207-1213; DOI: https://doi.org/10.2967/jnumed.120.260711

Oncology

  • Clinical

    • Value of <sup>18</sup>F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study
      You have access
      Value of 18F-FES PET in Solving Clinical Dilemmas in Breast Cancer Patients: A Retrospective Study
      Jorianne Boers, Naila Loudini, Celina L. Brunsch, Sylvia A. Koza, Erik F.J. de Vries, Andor W.J.M. Glaudemans, Geke A.P. Hospers and Carolina P. Schröder
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1214-1220; DOI: https://doi.org/10.2967/jnumed.120.256826
    • FEATURED CLINICAL INVESTIGATION ARTICLE

      • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
        You have access
        Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
        Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1221-1227; DOI: https://doi.org/10.2967/jnumed.120.252791

Basic

  • FEATURED ARTICLE OF THE MONTH

    • Synthesis and Preclinical Evaluation of a <sup>68</sup>Ga-Labeled Adnectin, <sup>68</sup>Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
      You have access
      Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
      Stephanie Robu, Antonia Richter, Dario Gosmann, Christof Seidl, David Leung, Wendy Hayes, Daniel Cohen, Paul Morin, David J. Donnelly, Daša Lipovšek, Samuel J. Bonacorsi, Adam Smith, Katja Steiger, Christina Aulehner, Angela M. Krackhardt and Wolfgang A. Weber
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1228-1234; DOI: https://doi.org/10.2967/jnumed.120.258384

Theranostics

  • Clinical

    • <sup>68</sup>Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma
      You have access
      68Ga-PSMA-11 PET/CT Improves Tumor Detection and Impacts Management in Patients with Hepatocellular Carcinoma
      Nader Hirmas, Catherine Leyh, Miriam Sraieb, Francesco Barbato, Benedikt M. Schaarschmidt, Lale Umutlu, Michael Nader, Heiner Wedemeyer, Justin Ferdinandus, Christoph Rischpler, Ken Herrmann, Pedro Fragoso Costa, Christian M. Lange, Manuel Weber and Wolfgang P. Fendler
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1235-1241; DOI: https://doi.org/10.2967/jnumed.120.257915
    • EDITORIAL

      • You have access
        PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
        Winfried Brenner, Joachim Strobel and Vikas Prasad
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1242-1243; DOI: https://doi.org/10.2967/jnumed.121.262737
    • The Impact of Monosodium Glutamate on <sup>68</sup>Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
      You have access
      The Impact of Monosodium Glutamate on 68Ga-PSMA-11 Biodistribution in Men with Prostate Cancer: A Prospective Randomized, Controlled Imaging Study
      Wesley R. Armstrong, Andrei Gafita, Shaojun Zhu, Pan Thin, Kathleen Nguyen, Rejah Alano, Stephanie Lira, Kiara Booker, Linda Gardner, Tristan Grogan, David Elashoff, Martin Allen-Auerbach, Magnus Dahlbom, Johannes Czernin and Jeremie Calais
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1244-1251; DOI: https://doi.org/10.2967/jnumed.120.257931
    • Combination of Forced Diuresis with Additional Late Imaging in <sup>68</sup>Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
      You have access
      Combination of Forced Diuresis with Additional Late Imaging in 68Ga-PSMA-11 PET/CT: Effects on Lesion Visibility and Radiotracer Uptake
      Ian Alberts, Jan Niklas-Hünermund, Christos Sachpekidis, Helle Damgaard Zacho, Clemens Mingels, Lotte Dijkstra, Karl Peter Bohn, Tilman Läppchen, Eleni Gourni, Axel Rominger and Ali Afshar-Oromieh
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1252-1257; DOI: https://doi.org/10.2967/jnumed.120.257741
    • Head-to-Head Comparison of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
      Open Access
      Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
      Melline G.M. Schilham, Patrik Zamecnik, Bastiaan M. Privé, Bas Israël, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah and Martin Gotthardt
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1258-1263; DOI: https://doi.org/10.2967/jnumed.120.258541
    • SUVs Are Adequate Measures of Lesional <sup>18</sup>F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
      You have access
      SUVs Are Adequate Measures of Lesional 18F-DCFPyL Uptake in Patients with Low Prostate Cancer Disease Burden
      Yves J.L. Bodar, Berend P.F. Koene, Bernard H.E. Jansen, Matthijs C.F. Cysouw, Dennie Meijer, N. Harry Hendrikse, André N. Vis, Ronald Boellaard and Daniela E. Oprea-Lager
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1264-1269; DOI: https://doi.org/10.2967/jnumed.120.260232
    • BRIEF COMMUNICATION

      • Detection of Early Progression with <sup>18</sup>F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
        You have access
        Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy
        Mark C. Markowski, Pedro Isaacsson Velho, Mario A. Eisenberger, Martin G. Pomper, Kenneth J. Pienta, Michael A. Gorin, Emmanuel S. Antonarakis, Samuel R. Denmeade and Steven P. Rowe
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1270-1273; DOI: https://doi.org/10.2967/jnumed.120.259226
    • BRIEF COMMUNICATION

      • Addition of <sup>131</sup>I-MIBG to PRRT (<sup>90</sup>Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
        Open Access
        Addition of 131I-MIBG to PRRT (90Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors
        David L. Bushnell, Kellie L. Bodeker, Thomas M. O’Dorisio, Mark T. Madsen, Yusuf Menda, Stephen Graves, Gideon K.D. Zamba and M. Sue O’Dorisio
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1274-1277; DOI: https://doi.org/10.2967/jnumed.120.254987
    • Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
      You have access
      Dual PET Imaging in Bronchial Neuroendocrine Neoplasms: The NETPET Score as a Prognostic Biomarker
      David L. Chan, Gary A. Ulaner, David Pattison, David Wyld, Rahul Ladwa, Julian Kirchner, Bob T. Li, W. Victoria Lai, Nick Pavlakis, Paul J. Roach and Dale L. Bailey
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1278-1284; DOI: https://doi.org/10.2967/jnumed.120.257659

ENDOCRINOLOGY

  • Assessment and Comparison of <sup>18</sup>F-Fluorocholine PET and <sup>99m</sup>Tc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
    You have access
    Assessment and Comparison of 18F-Fluorocholine PET and 99mTc-Sestamibi Scans in Identifying Parathyroid Adenomas: A Metaanalysis
    Julia Whitman, Isabel E. Allen, Emily K. Bergsland, Insoo Suh and Thomas A. Hope
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1285-1291; DOI: https://doi.org/10.2967/jnumed.120.257303

NEUROLOGY

  • Clinical

    • Tau<sup>IQ</sup>: A Canonical Image Based Algorithm to Quantify Tau PET Scans
      You have access
      TauIQ: A Canonical Image Based Algorithm to Quantify Tau PET Scans
      Alex Whittington, Roger N. Gunn and for the Alzheimer’s Disease Neuroimaging Initiative
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1292-1300; DOI: https://doi.org/10.2967/jnumed.120.258962
    • SPECIAL CONTRIBUTION

      • You have access
        Hypermetabolism on Pediatric PET Scans of Brain Glucose Metabolism: What Does It Signify?
        Harry T. Chugani
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1301-1306; DOI: https://doi.org/10.2967/jnumed.120.256081
  • Basic

    • Dopamine D<sub>1</sub> Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
      You have access
      Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
      Olivier Barret, Lei Zhang, David Alagille, Cristian C. Constantinescu, Christine Sandiego, Caroline Papin, Jenna M. Sullivan, Thomas Morley, Vincent M. Carroll, John Seibyl, Jianqing Chen, Chewah Lee, Anabella Villalobos, David Gray, Timothy J. McCarthy and Gilles Tamagnan
      Journal of Nuclear Medicine September 1, 2021, 62 (9) 1307-1313; DOI: https://doi.org/10.2967/jnumed.120.256008

MOLECULAR IMAGING

  • Basic

    • BRIEF COMMUNICATION

      • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
        You have access
        Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
        Samaneh Azargoshasb, Krijn H.M. Houwing, Paul R. Roos, Sven I. van Leeuwen, Michael Boonekamp, Elio Mazzone, Kevin Bauwens, Paolo Dell’Oglio, Fijs W.B. van Leeuwen and Matthias N. van Oosterom
        Journal of Nuclear Medicine September 1, 2021, 62 (9) 1314-1317; DOI: https://doi.org/10.2967/jnumed.120.259796

Challenging Case Studies

  • You have access
    Distinguishing Primary Lateral Sclerosis from Parkinsonian Syndromes with the Help of Advanced Imaging
    Pegah Masrori, Donatienne Van Weehaeghe, Koen Van Laere and Philip Van Damme
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1318-1319; DOI: https://doi.org/10.2967/jnumed.121.261942

Letters to the Editor

  • You have access
    Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
    Christopher E. Wee, Ayca Dundar, Rachel A. Eiring, Mohamed Badawy, Timothy J. Hobday, A. Tuba Kendi, Annie T. Packard and Thorvardur R. Halfdanarson
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1320; DOI: https://doi.org/10.2967/jnumed.121.262048
  • You have access
    Reply: Bowel Obstruction as a Complication of Peptide Receptor Radionuclide Therapy
    Jonathan R. Strosberg, Taymeyah Al-Toubah and Ghassan El-Haddad
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1321; DOI: https://doi.org/10.2967/jnumed.121.262340

SNMMI Newsline

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 8A;
  • You have access
    JNM 2020 Impact Factor Rises Sharply
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 9N;
  • You have access
    FDA Encourages Inclusion of Incurable Cancers in Trials
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 9N;
  • You have access
    ABNM Celebrating 50 Years
    George M. Segall
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 10N;
  • You have access
    Progress in Prostate Cancer Theranostics
    Richard L. Wahl
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 11N;
  • You have access
    Newsbriefs
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 12N-14N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 62 (9)
Journal of Nuclear Medicine
Vol. 62, Issue 9
September 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Sign up for alerts

Jump to

  • Editor’s Page
  • Discussions with Leaders
  • State of the Art
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Issues and Controversies
  • Oncology
    • Clinical
      • FEATURED CLINICAL INVESTIGATION ARTICLE
  • Basic
    • FEATURED ARTICLE OF THE MONTH
  • Theranostics
    • Clinical
      • EDITORIAL
      • BRIEF COMMUNICATION
      • BRIEF COMMUNICATION
  • ENDOCRINOLOGY
  • NEUROLOGY
    • Clinical
      • SPECIAL CONTRIBUTION
    • Basic
  • MOLECULAR IMAGING
    • Basic
      • BRIEF COMMUNICATION
  • Challenging Case Studies
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire